Clinical Trial Update: Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ Vaccine [Phase 3]

View source ↗

Summary

Phase 3 immunogenicity and safety study of GSK's Infanrix-IPV+Hib vaccine completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Haemophilus Influenzae Type Infection
• Pertussis
• Poliomyelitis
• Tetanus

Drugs mentioned

• Infanrix IPV/Hib (Diphtheria, Tetanus, Acellular Pertussis, Inactivated Poliovirus, Haemophilus influenzae type b vaccine (DTaP-IPV-Hib))

Snippet

Sponsor: GlaxoSmithKline | Conditions: Tetanus, Poliomyelitis | Phase 3 | Status: COMPLETED | Results posted: 2017-04-10